Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Improving Lipid Management for Patients Post-ACS

Improving Lipid Management for Patients Post-ACS

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

The role of the patient in Achieving LDL-C Target

The role of the patient in Achieving LDL-C Target

Identifying and treating patients with high Lipidaemia risk post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Watch Prof. Pasquale Perrone-Filardi from Department of Clinical Medicine, Cardiovascular and Immunology Sciences, Federico II University, Naples sharing insights on Identifying and treating patients with high lipidaemia risk post-ACS.

Effect of Alirocumab on MACE in patients with CKD

Effect of Alirocumab on MACE in patients with CKD

Lipid management in patients with ACS/ASCVD

Lipid management in patients with ACS/ASCVD

In hospital outcomes in young patients with AMI: Results from Gulf Coast

In hospital outcomes in young patients with AMI: Results from Gulf Coast

Adherence and persistence analysis in patients treated with DAPT

Adherence and persistence analysis in patients treated with DAPT

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Burden of Disease

Burden of Disease

DAPT in Elderly with CAD Meta Analysis

DAPT in Elderly with CAD Meta Analysis

Watch the video and get to know more on the crucial insights from this systematic review and meta-analysis of DAPT in elderly patients with acute coronary syndrome (ACS). Dual oral antiplatelet therapy (DAPT) with prasugrel or ticagrelor is associated with a higher risk of bleeding events in elderly patients with ACS compared to clopidogrel, with no difference in primary efficacy endpoint rates between the treatment groups.